Japan Hereditary Angioedema Market Insight
Published: 01 August 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The Japan Hereditary Angioedema Market will grow at a rate of 8.92% due to rising demand for targeted prophylactic therapeutics, hospital and rare disease center automation, the healthcare sector, and the increasing use of specialized plasma-derived and recombinant biological therapeutics for disease management in clinical care, emergency medicine, and clinical research.
Japan Hereditary Angioedema Market Insights Forecasts to 2035
- The Japan Hereditary Angioedema Market Size Was Estimated USD 142.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 8.92% from 2025 to 2035
- The Japan Hereditary Angioedema Market Size is Expected to rise around USD 335.6 Million by 2035
Notable Insights for the Japan Hereditary Angioedema Market
- Segmentation on the basis of Drug Class indicates that C1 Esterase Inhibitors and targeted kallikrein inhibitor therapies dominate Japan market in 2025 with 62.5% share across rare disease treatment industry.
- Segmentation on the basis of Treatment Type indicates that Prophylaxis Treatment segment dominates Japan Hereditary Angioedema Market 2025 with 68.3% share, driven by clinical adoption of long-term attack prevention therapies.
- World-wide projected revenue of Takeda Pharmaceutical Company Limited in fiscal year 2025 would be around $15.4 billion, owing to high demand for plasma-derived therapies, rare disease biopharmaceuticals, and specialized immunology treatments.
Download the eBook (ToC)
- It is expected that increasing diagnostic awareness, national rare disease registration frameworks, and approval of subcutaneous therapies would contribute in driving the growth of the market, where targeted kallikrein inhibition offers attack frequency reduction up to 87%, and minimizes acute hospital admissions up to 45%.
Why Buy This Report
- Gives an in-depth analysis of the impact of trends in rare disease diagnosis, modernization in hospital clinical care, and development in subcutaneous prophylactic biologic technology on the Japan Hereditary Angioedema Market growth.
- Provides strategic insights regarding technology innovation such as plasma-derived C1-INH concentrates, recombinant protein therapies, oral plasma kallikrein inhibitors, and RNA-based gene silencing platforms.
- Assists players to analyze competitive benchmarking, investment in biopharmaceutical manufacturing, automation in clinical research, and expansion in specialized immunology treatment centers by major rare disease therapeutic suppliers.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Hereditary Angioedema Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Hereditary Angioedema Market
- Takeda Pharmaceutical Company Limited
- CSL Behring KK
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- KalVista Pharmaceuticals, Inc.
- Astria Therapeutics, Inc.
- Intellia Therapeutics, Inc.
- Regeneron Pharmaceuticals, Inc.
- Ono Pharmaceutical Co., Ltd.
Recent Developments:
- In January 2026, Takeda Pharmaceutical Company Limited received expanded approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its subcutaneous C1 esterase inhibitor formulation for pediatric routine prophylaxis in hereditary angioedema.
- In September 2025, CSL Behring KK entered into a strategic distribution collaboration with local Japanese healthcare logistics network partners to streamline cold-chain distribution of plasma-derived therapy across designated rare disease treatment hospitals.
Market Segmentation:
Japan Hereditary Angioedema Market, By Drug Class
- C1 Esterase Inhibitors (C1-INH)
- Kallikrein Inhibitors
- Bradykinin B2 Receptor Antagonists
- Attenuated Androgens
- RNAi / Gene Therapies
Japan Hereditary Angioedema Market, By Treatment Type
- Prophylaxis Treatment (Long-Term & Short-Term)
- On-Demand Acute Attack Management
- Gene Silencing & Target Therapies
Japan Hereditary Angioedema Market, By Route of Administration
- Subcutaneous
- Intravenous
- Oral
Expert Views:
The market for hereditary angioedema treatments in Japan will grow owing to the rise in the demand for targeted prophylactic biological therapies, the growing number of early diagnostic screening programs, and increasing demand for subcutaneous self-administration options. The inclusion of plasma-derived protein replacement solutions, oral kallikrein targeted monitoring therapies, and recombinant enzyme treatments will enhance clinical outcome efficiency and boost the demand for hereditary angioedema therapeutics in the Japanese market.
Author: Govind and Krishna By Decisions Advisors and Consulting